Gilteritinib

Independent reference data for Gilteritinib (CAS 1254053-43-4), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Gilteritinib is an orally available small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) which is used as an antineoplastic agent in the treatment of acute myeloid leukemia with FLT3 mutations. Gilteritinib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors

Synonyms and trade names

Gilteritinib; 1254053-43-4; ASP2215; ASP-2215; gilteritinibum; ASP 2215; 66D92MGC8M; CHEBI:145372; DTXSID701027949; RefChem:58108; L01XE54; DTXCID601513517; MFCD28144685; Gilteritinib HCl; Gilteritinib [USAN:INN]; UNII-66D92MGC8M

GHS hazard classification

Reported hazard statements	H360 (100%), H373 (100%)

H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]

H373 (100%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

What the public record says

Gilteritinib · CAS 1254053-43-4 · C29H44N8O3. UNII 66D92MGC8M. Boiling Point: 696; Solubility: <1 mg/mL; LogP: 4.35.

Source: PubChem / Wikidata; the batch COA governs where values differ.